Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VioQuest Pharmaceuticals has initiated an open-label Phase IIa study of Lenocta, a novel protein tyrosine phosphatase inhibitor, in combination with interferon alpha, in patients with advanced-stage solid tumors.
Subscribe to our email newsletter
The company has announced the dosing of the first patient and the study is designed to enroll at least 12 more patients. The trial will evaluate the clinical efficacy and biological effectiveness of Lenocta (sodium stibogluconate) at the highest tolerable dose in combination with interferon alpha in solid tumors patients.
Michael Becker, president and CEO of VioQuest, said: “We have reached a significant milestone in the development of Lenocta as a potential cancer therapy with the initiation of this trial. We will continue to advance our portfolio of novel compounds for various cancer indications into clinical development, the goal of this drug development organization.”